Lead sponsor
Ascletis Pharma (China) Co., Limited
5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
5
Trials led
2
Active
440
Total enrollment
13
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 1/2
1
Phase 2
2
Trials by status
Active, not recruiting
2
Completed
3
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities—Ph 2Completed125
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity—Ph 1/2Active, not recruiting115
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusBMI ≥23Ph 2Active, not recruiting100